

INC Research Holdings, Inc.  
Form 8-K  
October 03, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 1, 2016**

**INC RESEARCH HOLDINGS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36730**  
**(Commission**  
  
**File Number)**

**27-3403111**  
**(IRS Employer**  
  
**Identification No.)**

**3201 Beechleaf Court, Suite 600**  
**Raleigh, North Carolina**

**27604-1547**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (919) 876-9300**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(c), (e) On October 1, 2016, INC Research Holdings, Inc. (the Company) appointed Michael Gibertini, PhD, who already was an executive officer, to Chief Operating Officer of the Company.

The Company did not amend Dr. Gibertini's current employment agreement in connection with his appointment. Dr. Gibertini's Executive Service Agreement, a summary of such agreement, and Dr. Gibertini's biographical information are included in the Company's Form 10-K for the fiscal year ended December 31, 2015 filed with the U.S. Securities and Exchange Commission on February 25, 2016, as amended on March 14, 2016, and are incorporated herein by reference.

There are no related party transactions between Dr. Gibertini and the Company that require disclosure in this Form 8-K under Regulation S-K Item 404(a). A copy of the press release regarding the above matters is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

| <b>ExhibitNo.</b> | <b>Description of Document</b>      |
|-------------------|-------------------------------------|
| 99.1              | Press Release dated October 3, 2016 |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 3, 2016

**INC RESEARCH HOLDINGS, INC.**

By: /s/ Christopher L. Gaenzle

Name: Christopher L. Gaenzle

Title: Chief Administrative Officer and General Counsel